Home » Case Studies » Value Access and Pricing » Early Payer Guidance

Early Payer Guidance

CBPartners recently completed an early payer guidance engagement, conducting comprehensive secondary research across four inflammatory disease areas.


Provide the client team with a robust background in rheumatoid arthritis, osteoarthritis, idiopathic pulmonary fibrosis, and systemic sclerosis to advise early stage decision-making.



Conduct comprehensive secondary research in the following areas: disease background including diagnosis, prognosis, epidemiology and unmet needs; current and future paradigm including lines of therapies and standard of care; pipeline analysis including key therapies in development and future treatment gamechangers; and pricing and access landscape including pricing analysis, health technology assessment (HTA) outcomes and access status.


Four disease-specific early payer guidance reports powered by comprehensive secondary research efforts into disease background, current and future treatment paradigm, pipeline analysis and pricing and access landscape.

Illustrative Outputs


CBP conducted comprehensive secondary research and landscape analyses to help provide early payer guidance across therapeutic areas of interest from a future business development perspective.